These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Closing the Equity Gap: Early Intervention in Sickle Cell Disease. Williams AR; Archer NM Pediatrics; 2024 Jul; 154(1):. PubMed ID: 38836305 [No Abstract] [Full Text] [Related]
4. The changing face of international medicine. Coltart C Clin Med (Lond); 2012 Oct; 12(5):405-6. PubMed ID: 23101136 [No Abstract] [Full Text] [Related]
7. Barriers and facilitators to community acceptability of integrating point-of-care testing to screen for sickle cell disease in children in primary healthcare settings in rural Upper East Region of Northern Ghana. Chatio ST; Duah E; Ababio LO; Lister N; Egbujo O; Marfo K; Aborigo R; Ansah P; Odame I PLoS One; 2024; 19(5):e0303520. PubMed ID: 38768171 [TBL] [Abstract][Full Text] [Related]
8. Community health workers in India should be trained to offer genetic counselling for rare diseases. Patel D; Kumar R Nat Med; 2024 Feb; 30(2):319. PubMed ID: 38200260 [No Abstract] [Full Text] [Related]
9. Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions? Hegemann L; Narasimhan V; Marfo K; Kuma-Aboagye P; Ofori-Acquah S; Odame I Ann Glob Health; 2023; 89(1):76. PubMed ID: 38025926 [TBL] [Abstract][Full Text] [Related]
10. Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease. Vunnam N; Hansen S; Williams DC; Been MO; Lo CH; Pandey AK; Paulson CN; Rohde JA; Thomas DD; Sachs JN; Wood DK Biomacromolecules; 2022 Sep; 23(9):3822-3830. PubMed ID: 35944154 [TBL] [Abstract][Full Text] [Related]
11. Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases. Alabi OJ; Adegboyega FN; Olawoyin DS; Babatunde OA Heliyon; 2022 Jun; 8(6):e09630. PubMed ID: 35677416 [TBL] [Abstract][Full Text] [Related]
12. A retrospective case study of successful translational research: Gazelle Hb variant point-of-care diagnostic device for sickle cell disease. Qua K; Swiatkowski SM; Gurkan UA; Pelfrey CM J Clin Transl Sci; 2021; 5(1):e207. PubMed ID: 35047218 [TBL] [Abstract][Full Text] [Related]
13. Menstrual characteristics of sickle cell disease patients seen at a tertiary institution in North Western Nigeria. Mohammed-Durosinlorun A; Bello-Manga H; Adze J; Ijei IP; Stephen B Ann Afr Med; 2021; 20(4):255-264. PubMed ID: 34893562 [TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 gene editing for curing sickle cell disease. Park SH; Bao G Transfus Apher Sci; 2021 Feb; 60(1):103060. PubMed ID: 33455878 [TBL] [Abstract][Full Text] [Related]
15. Feasibility and acceptability of early infant screening for sickle cell disease in Lagos, Nigeria-A pilot study. Oluwole EO; Adeyemo TA; Osanyin GE; Odukoya OO; Kanki PJ; Afolabi BB PLoS One; 2020; 15(12):e0242861. PubMed ID: 33270733 [TBL] [Abstract][Full Text] [Related]